These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37847244)

  • 1. Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists.
    Khalaf JK; Bess LS; Walsh LM; Ward JM; Johnson CL; Livesay MT; Jackson KJ; Evans JT; Ryter KT; Bazin-Lee HG
    J Med Chem; 2023 Oct; 66(20):13900-13917. PubMed ID: 37847244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
    Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
    Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking toll: lipid A mimetics as adjuvants and immunomodulators.
    Persing DH; Coler RN; Lacy MJ; Johnson DA; Baldridge JR; Hershberg RM; Reed SG
    Trends Microbiol; 2002; 10(10 Suppl):S32-7. PubMed ID: 12377566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR4 agonists as immunomodulatory agents.
    Alderson MR; McGowan P; Baldridge JR; Probst P
    J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface immunogenic protein from Streptococcus agalactiae and
    Díaz-Dinamarca DA; Salazar ML; Escobar DF; Castillo BN; Valdebenito B; Díaz P; Manubens A; Salazar F; Troncoso MF; Lavandero S; Díaz J; Becker MI; Vásquez AE
    Front Immunol; 2023; 14():1186188. PubMed ID: 37790926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    mBio; 2017 May; 8(3):. PubMed ID: 28487429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of adjuvants to optimize influenza neutralizing antibody responses.
    Rudicell RS; Garinot M; Kanekiyo M; Kamp HD; Swanson K; Chou TH; Dai S; Bedel O; Simard D; Gillespie RA; Yang K; Reardon M; Avila LZ; Besev M; Dhal PK; Dharanipragada R; Zheng L; Duan X; Dinapoli J; Vogel TU; Kleanthous H; Mascola JR; Graham BS; Haensler J; Wei CJ; Nabel GJ
    Vaccine; 2019 Sep; 37(42):6208-6220. PubMed ID: 31493950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics.
    Johnson DA
    Curr Top Med Chem; 2008; 8(2):64-79. PubMed ID: 18289078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants.
    Fuentes R; Aguinagalde L; Pifferi C; Plata A; Sacristán N; Castellana D; Anguita J; Fernández-Tejada A
    Front Immunol; 2022; 13():865507. PubMed ID: 35603193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship of synthetic toll-like receptor 4 agonists.
    Stöver AG; Da Silva Correia J; Evans JT; Cluff CW; Elliott MW; Jeffery EW; Johnson DA; Lacy MJ; Baldridge JR; Probst P; Ulevitch RJ; Persing DH; Hershberg RM
    J Biol Chem; 2004 Feb; 279(6):4440-9. PubMed ID: 14570885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of Heterologous Simian Immunodeficiency Virus SIV
    Singh S; Ramírez-Salazar EG; Doueiri R; Valentin A; Rosati M; Hu X; Keele BF; Shen X; Tomaras GD; Ferrari G; LaBranche C; Montefiori DC; Das J; Alter G; Trinh HV; Hamlin C; Rao M; Dayton F; Bear J; Chowdhury B; Alicea C; Lifson JD; Broderick KE; Sardesai NY; Sivananthan SJ; Fox CB; Reed SG; Venzon DJ; Hirsch VM; Pavlakis GN; Felber BK
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
    Hawkins LD; Ishizaka ST; McGuinness P; Zhang H; Gavin W; DeCosta B; Meng Z; Yang H; Mullarkey M; Young DW; Yang H; Rossignol DP; Nault A; Rose J; Przetak M; Chow JC; Gusovsky F
    J Pharmacol Exp Ther; 2002 Feb; 300(2):655-61. PubMed ID: 11805229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
    Reed SG; Hsu FC; Carter D; Orr MT
    Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.
    Fox CB; Friede M; Reed SG; Ireton GC
    Subcell Biochem; 2010; 53():303-21. PubMed ID: 20593273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
    Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
    Front Immunol; 2018; 9():381. PubMed ID: 29541075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.